NHS in England Approves Fampridine for Multiple Sclerosis Patients

New Delhi, India Jul 23, 2026 ALN: The first drug to help people with multiple sclerosis walk is being made available on the NHS in England.

Fampridine boosts nerve signals to make it easier for some people to move and live independently. This marks a significant development in the treatment options available for patients suffering from multiple sclerosis (MS), a chronic disease that affects the central nervous system, leading to a range of physical and cognitive disabilities.

Aysen Slack, who used to pay for fampridine privately until it became too costly, expressed her relief and optimism regarding the NHS's decision, stating that it would make a "huge difference" in her daily life. Her experience highlights the financial burden that many patients face when seeking effective treatments for their conditions. Up to 5,000 people in England could benefit each year from this drug, which has already been available in other parts of the UK, including Wales, Scotland, and Northern Ireland.

Multiple sclerosis is caused by the immune system attacking the protective covering around nerve cells, known as myelin. This damage impairs the ability of nerves to carry electrical messages from the brain to the rest of the body, including those needed for the precise control of muscles required for walking. The impact of MS can vary widely among individuals, with some experiencing mild symptoms while others face severe mobility challenges. Fampridine is classified as a "signal booster" because it enhances the transmission of these electrical signals, allowing for improved communication between the brain and muscles.

Clinical trials have shown promising results, indicating that around four in ten individuals taking fampridine experienced improvements in their walking speed and endurance. These enhancements could significantly affect the quality of life for patients, enabling them to perform daily tasks more easily, engage in social activities, and maintain a level of independence that many take for granted. The ability to move around the house without assistance or to visit friends and family can dramatically enhance a person’s mental and emotional well-being.

Currently, NHS support for MS patients includes physiotherapy and walking aids, which are essential in managing the condition. However, the introduction of fampridine represents a new avenue for treatment that can complement existing therapies. Previously, fampridine was rejected for use by the NHS in England due to concerns over its cost-effectiveness. This decision was met with disappointment by many patients and advocacy groups who believed in the drug's potential benefits. In contrast, it was made available in Wales, Scotland, and Northern Ireland, highlighting a disparity in healthcare access across the UK.

'Clear benefit'

Aysen Slack, 65 and from Eastbourne, chose to pay privately for the pills once she learned about their potential benefits. She shared her experience, stating that fampridine was "working well for me" but the financial burden became unsustainable, leading her to discontinue its use. Slack's story is a poignant reminder of the challenges faced by individuals with chronic conditions, who often must navigate not only their health issues but also the financial implications of their treatment options. She expressed her hope that with fampridine now available through the NHS, she would be able to try the medication again, emphasizing that her mobility has significantly decreased, necessitating the use of walking sticks even within her own home. The prospect of regaining some mobility is an important aspect of her quality of life.

More than 120,000 people live with MS in England, and while the new approval for fampridine is a positive development, it is important to note that only around 5,000 individuals per year will be eligible for the treatment based on the severity of their walking difficulties. This limitation underscores the need for continued research and development of therapies that can address the needs of a broader range of patients. The treatment protocol for fampridine involves patients trying the medication for up to a month, after which only those who demonstrate a "clear benefit" will be allowed to continue taking it. This approach aims to ensure that the drug is used effectively and that resources are allocated to those who are most likely to benefit.

Prof Frankie Swords, the NHS national medical director, commented on the significance of this approval, stating that walking difficulties can profoundly impact the freedom and independence of individuals with MS. He noted that even a modest improvement in mobility could lead to substantial changes in a person's ability to navigate their environment, engage with their community, and live more independently. This perspective aligns with the broader goals of healthcare systems to enhance the quality of life for patients by providing access to effective treatments.

Ceri Smith, from the MS Society, expressed the organization's delight at the announcement, emphasizing that fampridine could be "life-changing" for many individuals. The ability to improve mobility can empower patients to live more independently or maintain employment, which is crucial for their financial and emotional stability. The MS Society has long advocated for better access to treatments and support for individuals living with this challenging condition, and the approval of fampridine represents a step forward in that mission.

In conclusion, the NHS's decision to approve fampridine for multiple sclerosis patients in England is a significant milestone that could greatly enhance the lives of thousands of individuals living with this condition. By improving mobility and independence, fampridine not only addresses a critical medical need but also contributes to the overall well-being of patients and their families. As the healthcare landscape continues to evolve, the focus on patient-centered care and access to innovative treatments remains paramount in the fight against chronic diseases like multiple sclerosis.